You can discover more insights about these pharma sales trends on emarketer.com
While the metabolic effects of GLP-1s are well-documented, many users are now noticing unexpected changes in their skin health and appearanceespecially with rapid weight loss
Triple agonists like retatrutide 12 mg have demonstrated approximately 28.7% average weight loss over 68 weeks in Phase 3 trials
Novo Nordisk fights back with oral GLP-1 data in obesity Shortly after reporting weaker-than-expected sales of its injectable GLP-1 drugs, Novo Nordisk revealed clinical results with an oral alternative that suggest it can offer comparable efficacy with convenient, daily dosing
Quantity, format, packaging notes and the related product category are the most important details to check
The question is which patient gets which agent, at what dose, and in what combination